retatrutide mechanism triple agonist glp-1 gip glucagon ly3437943 Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Acute Contractile Effects of Glucagon-like-Peptide-1

The improvement happens gradually rather than overnight

Dopamine and the reward pathway Dopamine is the neurotransmitter of wanting

This emerged from the work of Janet Mertz, Paul Berg, and Stanley Cohen at Stanford University and Herbert Boyer at the University of California San Francisco

How retatrutide works Retatrutide is a once-a-week injection

Note that there are drugs in development as sub-cutaneous (SC) administration (like current Ozempic, Wegovy, Zepbound, Mounjaro), whilst we wont need to wait to long for the oral versions of these drugs to come out (next 6-12 months)

Research shows a rare but possible connection to NAION, especially in people with type 2 diabetes